PMCB

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

PharmaCyte Biotech Inc

NASDAQ | PMCB

0.95

USD

$0.00

(

0.00%

)

At Close (As of Oct 23, 2025)

$6.52M

Market Cap

16

P/E Ratio

0.06

EPS

$2.42

52 Week High

$0.80

52 Week Low

HEALTHCARE

Sector

PMCB Chart

Recent Chart
Price Action

PMCB Technicals

Tags:

PMCB Earnings

Yearly Income Statement (As of Apr 30, 2025)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$4.4M
Selling General And Administrative $3.9M
Research And Development $438K
Operating Expenses $4.4M
Investment Income Net -
Net Interest Income $1.4M
Interest Income $1.4M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax $31M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations $31M
Comprehensive Income Net Of Tax -
Ebit -$4.4T
Ebitda $31M
Net Income $31M

Revenue & Profitability

Earnings Performance

PMCB Financials

yearly Balance Sheet (As of Apr 30, 2025)

Field Value (USD)
Total Assets $55M
Total Current Assets $22M
Cash And Cash Equivalents At Carrying Value $15M
Cash And Short Term Investments $15M
Inventory -
Current Net Receivables $3.7M
Total Non Current Assets $33M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $1.5M
Intangible Assets Excluding Goodwill $1.5M
Goodwill -
Investments -
Long Term Investments $22M
Short Term Investments $366K
Other Current Assets $3.1M
Other Non Current Assets -
Total Liabilities $3.3M
Total Current Liabilities $2.9M
Current Accounts Payable $399K
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $363K
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $2.5M
Other Non Current Liabilities -
Total Shareholder Equity $52M
Treasury Stock -
Retained Earnings -$85M
Common Stock $2.2K
Common Stock Shares Outstanding $7.3M

yearly Cash Flow (As of Apr 30, 2025)

Field Value (USD)
Operating Cashflow -$3M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $4
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$7M
Cashflow From Financing -$25M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout $1.1M
Dividend Payout Common Stock $1.1M
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$25M
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $31M

yearly Income Statement (As of Apr 30, 2025)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$4.4M
Selling General And Administrative $3.9M
Research And Development $438K
Operating Expenses $4.4M
Investment Income Net -
Net Interest Income $1.4M
Interest Income $1.4M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax $31M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations $31M
Comprehensive Income Net Of Tax -
Ebit -$4.4T
Ebitda $31M
Net Income $31M

PMCB News

PMCB Profile

PharmaCyte Biotech Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

PharmaCyte Biotech Inc. (PMCB) is a clinical-stage biotechnology company headquartered in Laguna Hills, California, focused on developing cutting-edge cell therapies for cancer and diabetes. Utilizing its proprietary technology platform, the company aims to create transformative treatments that enhance patient outcomes and overall quality of life. With a strategic emphasis on advancing its clinical programs, PharmaCyte Biotech is well-positioned to make significant contributions to the rapidly evolving biopharmaceutical sector, potentially addressing unmet medical needs and driving value for investors.

YYAI
-50.60%
$0.09
BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
YDKG
+5.58%
$0.07
F
-0.72%
$12.34
CGBS
-39.47%
$0.03
VHAI
0.00%
$0.00
RGTI
+9.80%
$39.59
AIRE
+38.18%
$0.98
RIG
+13.74%
$3.89
TSLA
+2.28%
$448.98
INTC
+3.35%
$38.15
BURU
-5.27%
$0.34
VTYX
+70.98%
$6.60
NOK
+11.17%
$6.17
QBTS
+13.81%
$31.06
NVDA
+1.04%
$182.16
T
-3.63%
$24.62
ADAP
-3.44%
$0.07
MSAI
+101.73%
$1.35
AAL
+5.62%
$12.77
BITF
+5.71%
$4.16
VIVK
+5.68%
$0.26
WTO
-7.04%
$0.06
IONZ
-14.59%
$3.98
AREB
+75.34%
$3.77
AXDX
-61.36%
$0.03
DNN
+0.36%
$2.73
IONQ
+7.06%
$59.37
PLUG
-1.36%
$2.88
ABEV
+0.45%
$2.21
SMCI
-8.72%
$47.92
QUBT
+7.19%
$15.94
TLRY
+2.06%
$1.48
VZ
-3.51%
$38.40
RGTZ
-20.27%
$14.90
GRAB
+1.77%
$5.72
SOFI
+3.27%
$28.08
RBNE
+7.87%
$1.37
BBD
+1.51%
$3.35
JOBY
+1.29%
$15.67
RF
-0.04%
$24.10
CAN
+3.22%
$1.76
ETHD
-3.17%
$3.97
ACHR
+0.46%
$10.91
QS
+7.95%
$14.66
RMBL
+60.50%
$3.21
SGBX
+29.82%
$2.96
AMD
+2.06%
$234.99
BTG
+0.38%
$5.23
ADD
-25.47%
$0.05
VLY
+4.24%
$10.56
ONDS
+4.74%
$7.06
GPUS
-0.28%
$0.38
PLTR
+2.84%
$180.48
LAES
+5.92%
$5.72
RXRX
-0.34%
$5.73
SRM
+53.27%
$10.30
CIFR
+7.10%
$17.25
PFE
-0.20%
$24.67
TNGX
-13.04%
$7.53
UUUU
-6.50%
$21.26
BTBT
+3.62%
$3.72
AAPL
+0.43%
$259.58
MARA
+0.36%
$19.22
AMC
-0.72%
$2.73
DVLT
+5.14%
$2.25
WBD
+3.50%
$21.25
AMZN
+1.44%
$221.09
IREN
+7.77%
$55.86
HPE
+0.43%
$23.19
PBR
+0.93%
$11.84
NIO
+0.73%
$6.89
IBIO
-8.63%
$1.27
CUTR
-10.19%
$0.09
KMI
-4.75%
$26.25
NVTS
+0.03%
$13.61
WLGS
-5.57%
$0.04
SOUN
+2.70%
$18.23
LUV
-6.25%
$31.65
RR
+7.11%
$5.42
TE
-9.73%
$3.71
ETWO
0.00%
$3.30
SCWO
+32.07%
$0.48
SNAP
+1.28%
$7.87
BAC
+1.29%
$51.76
RIVN
+1.31%
$13.09
BTE
+5.72%
$2.40
APLD
+9.01%
$33.38
DNUT
+1.98%
$4.11
HOOD
+5.58%
$134.33
LUMN
+10.65%
$7.79
VALE
-0.52%
$11.46
AFMD
-34.94%
$0.18
NCLH
-0.63%
$23.48
ERIC
-0.31%
$9.48
CLSK
+4.80%
$17.67
KDLY
+10.41%
$0.79
ELBM
+3.61%
$1.72
NAKA
+10.41%
$0.79
YYAI
-50.60%
$0.09
BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
YDKG
+5.58%
$0.07
F
-0.72%
$12.34
CGBS
-39.47%
$0.03
VHAI
0.00%
$0.00
RGTI
+9.80%
$39.59
AIRE
+38.18%
$0.98
RIG
+13.74%
$3.89
TSLA
+2.28%
$448.98
INTC
+3.35%
$38.15
BURU
-5.27%
$0.34
VTYX
+70.98%
$6.60
NOK
+11.17%
$6.17
QBTS
+13.81%
$31.06
NVDA
+1.04%
$182.16
T
-3.63%
$24.62
ADAP
-3.44%
$0.07
MSAI
+101.73%
$1.35
AAL
+5.62%
$12.77
BITF
+5.71%
$4.16
VIVK
+5.68%
$0.26
WTO
-7.04%
$0.06
IONZ
-14.59%
$3.98
AREB
+75.34%
$3.77
AXDX
-61.36%
$0.03
DNN
+0.36%
$2.73
IONQ
+7.06%
$59.37
PLUG
-1.36%
$2.88
ABEV
+0.45%
$2.21
SMCI
-8.72%
$47.92
QUBT
+7.19%
$15.94
TLRY
+2.06%
$1.48
VZ
-3.51%
$38.40
RGTZ
-20.27%
$14.90
GRAB
+1.77%
$5.72
SOFI
+3.27%
$28.08
RBNE
+7.87%
$1.37
BBD
+1.51%
$3.35
JOBY
+1.29%
$15.67
RF
-0.04%
$24.10
CAN
+3.22%
$1.76
ETHD
-3.17%
$3.97
ACHR
+0.46%
$10.91
QS
+7.95%
$14.66
RMBL
+60.50%
$3.21
SGBX
+29.82%
$2.96
AMD
+2.06%
$234.99
BTG
+0.38%
$5.23
ADD
-25.47%
$0.05
VLY
+4.24%
$10.56
ONDS
+4.74%
$7.06
GPUS
-0.28%
$0.38
PLTR
+2.84%
$180.48
LAES
+5.92%
$5.72
RXRX
-0.34%
$5.73
SRM
+53.27%
$10.30
CIFR
+7.10%
$17.25
PFE
-0.20%
$24.67
TNGX
-13.04%
$7.53
UUUU
-6.50%
$21.26
BTBT
+3.62%
$3.72
AAPL
+0.43%
$259.58
MARA
+0.36%
$19.22
AMC
-0.72%
$2.73
DVLT
+5.14%
$2.25
WBD
+3.50%
$21.25
AMZN
+1.44%
$221.09
IREN
+7.77%
$55.86
HPE
+0.43%
$23.19
PBR
+0.93%
$11.84
NIO
+0.73%
$6.89
IBIO
-8.63%
$1.27
CUTR
-10.19%
$0.09
KMI
-4.75%
$26.25
NVTS
+0.03%
$13.61
WLGS
-5.57%
$0.04
SOUN
+2.70%
$18.23
LUV
-6.25%
$31.65
RR
+7.11%
$5.42
TE
-9.73%
$3.71
ETWO
0.00%
$3.30
SCWO
+32.07%
$0.48
SNAP
+1.28%
$7.87
BAC
+1.29%
$51.76
RIVN
+1.31%
$13.09
BTE
+5.72%
$2.40
APLD
+9.01%
$33.38
DNUT
+1.98%
$4.11
HOOD
+5.58%
$134.33
LUMN
+10.65%
$7.79
VALE
-0.52%
$11.46
AFMD
-34.94%
$0.18
NCLH
-0.63%
$23.48
ERIC
-0.31%
$9.48
CLSK
+4.80%
$17.67
KDLY
+10.41%
$0.79
ELBM
+3.61%
$1.72
NAKA
+10.41%
$0.79
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.